139 related articles for article (PubMed ID: 8391243)
1. Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice.
Tong AW; Huang YW; Zhang BQ; Netto G; Vitetta ES; Stone MJ
Anticancer Res; 1993; 13(3):593-7. PubMed ID: 8391243
[TBL] [Abstract][Full Text] [Related]
2. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease.
Huang YW; Richardson JA; Tong AW; Zhang BQ; Stone MJ; Vitetta ES
Cancer Res; 1993 Mar; 53(6):1392-6. PubMed ID: 8443818
[TBL] [Abstract][Full Text] [Related]
3. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells.
Huang YW; Richardson JA; Vitetta ES
Cancer Res; 1995 Feb; 55(3):610-6. PubMed ID: 7834632
[TBL] [Abstract][Full Text] [Related]
5. Evolution of clonality and invasive behavior of Epstein-Barr virus immortalized lymphoblastoid cell lines in SCID mice brains.
Bashir R; Masih A; Kallweit K; Fordyce-Boyer R; Sanger W; Purtilo D
Lab Invest; 1992 Oct; 67(4):450-6. PubMed ID: 1331608
[TBL] [Abstract][Full Text] [Related]
6. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N
Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027
[TBL] [Abstract][Full Text] [Related]
8. An in vivo model of human multiple myeloma bone disease.
Alsina M; Boyce BF; Mundy GR; Roodman GD
Stem Cells; 1995 Aug; 13 Suppl 2():48-50. PubMed ID: 8520511
[TBL] [Abstract][Full Text] [Related]
9. Elimination of chemoresistant multiple myeloma clonogenic colony-forming cells by combined treatment with a plasma cell-reactive monoclonal antibody and a P-glycoprotein-reactive monoclonal antibody.
Tong AW; Lee J; Wang RM; Dalton WS; Tsuruo T; Fay JW; Stone MJ
Cancer Res; 1989 Sep; 49(17):4829-34. PubMed ID: 2569359
[TBL] [Abstract][Full Text] [Related]
10. Selective depletion of human myeloma clonogenic stem cells from bone marrow cell preparations by a plasma-cell reactive antibody and complement.
Stone MJ; Tong AW; Fay JW; Lee JC
Cancer Detect Prev; 1988; 12(1-6):621-35. PubMed ID: 3180147
[TBL] [Abstract][Full Text] [Related]
11. The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines.
Coleman EJ; Brooks KJ; Smallshaw JE; Vitetta ES
J Immunother; 2006; 29(5):489-98. PubMed ID: 16971805
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
[TBL] [Abstract][Full Text] [Related]
13. Control of human B cell tumor growth in severe combined immunodeficiency mice by monoclonal anti-B cell antibodies.
Durandy A; Brousse N; Rozenberg F; De Saint Basile G; Fischer AM; Fischer A
J Clin Invest; 1992 Sep; 90(3):945-52. PubMed ID: 1326002
[TBL] [Abstract][Full Text] [Related]
14. Growth and dissemination of human malignant melanoma cells in mice with severe combined immune deficiency.
Taylor CW; Grogan TM; Lopez MH; Leong SP; Odeleye A; Feo-Zuppardi FJ; Hersh EM
Lab Invest; 1992 Jul; 67(1):130-7. PubMed ID: 1625443
[TBL] [Abstract][Full Text] [Related]
15. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice.
Hjorth-Hansen H; Seifert MF; Börset M; Aarset H; Ostlie A; Sundan A; Waage A
J Bone Miner Res; 1999 Feb; 14(2):256-63. PubMed ID: 9933480
[TBL] [Abstract][Full Text] [Related]
16. [Molecular pathological characteristics of human B-cell lymphomas induced by Epstein-Barr virus].
Gan RL; Yin ZH; Liu TF; Dong BH; Zhou JG; Yao KT
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):925-9. PubMed ID: 14515211
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a novel malignant B cell line with t(14;18) and t(4;11) established from a patient with acute monoblastic leukemia.
de Kroon JF; Kluin-Nelemans HC; Kluin PM; Schuuring E; van Bergen CA; Oving I; Wessels H; Willemze R; Falkenburg JH
Exp Hematol; 1997 Sep; 25(10):1062-8. PubMed ID: 9293903
[TBL] [Abstract][Full Text] [Related]
18. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
[TBL] [Abstract][Full Text] [Related]
19. Tumorigenesis of Epstein-Barr virus-positive epithelial cell lines derived from gastric tissues in the SCID mouse.
Murakami M; Hoshikawa Y; Satoh Y; Ito H; Tajima M; Okinaga K; Miyazawa Y; Kurata T; Sairenji T
Virology; 2000 Nov; 277(1):20-6. PubMed ID: 11062032
[TBL] [Abstract][Full Text] [Related]
20. An antigenic study of human plasma cells in normal tissue and in myeloma: identification of a novel plasma cell associated antigen.
Nathan PD; Walker L; Hardie D; Richardson P; Khan M; Johnson GD; Ling NR
Clin Exp Immunol; 1986 Jul; 65(1):112-9. PubMed ID: 3024883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
